Abstracts tagged "depression"

Abstract Number: 0018 • ACR Convergence 2020
PROMIS-29 and Health Related Quality of Life in Rheumatology Outpatients During the COVID-19 Pandemic in New York City
Gregory Vitone¹, Marianna Frey², Candace Feldman³, Lindsay Lally², Anne Bass⁴, Jane Salmon², Mary Crow², Michael Lockshin⁵, Vivian Bykerk², Medha Barbhaiya⁵ and Lisa Mandl², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, ³Brigham and Women's Hospital, Boston, MA, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Little is known about the general health and wellbeing of patients with systemic rheumatic diseases (SRD) during the COVID pandemic. We sought to compare…
Abstract Number: 1320 • ACR Convergence 2020
Are Coping Strategies, Anxiety and Depression Associated with Daily Physical Activity in Patient with Axial SpA?
Marllies Carbo¹, Laura van Overbeeke², Yvo Kamsma³, Freke Wink⁴, Suzanne Arends⁴, Davy Paap⁵ and Anneke Spoorenberg⁴, ¹University Medical Centre Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology University Medical Centre Groningen, Groningen, Netherlands, ³Center for Human Movement Sciences, Groningen, Groningen, Netherlands, ⁴University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands, ⁵, Department of Rehabilitation Medicine, University of Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Background: Patients with axial spondyloarthritis (axSpA) who are more physically active experience less pain and better physical functioning. It is also known that psychological…
Abstract Number: 0166 • ACR Convergence 2020
Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey
Alexis Ogdie¹, George Gondo², Joseph Merola³, Stacie Bell⁴ and Alice Gottlieb⁵, ¹University of Pennsylvania, Philadelphia, PA, ²National Psoriasis Foundation, Portland, OR, ³Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ⁴National Psoriasis Foundation, Portland, ⁵Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Despite many efficacious therapies for PsA, many patients do not achieve remission. Ongoing disease activity leads to many downstream effects including diminished functional ability,…
Abstract Number: 1598 • ACR Convergence 2020
Efficacy of Universal Depression Screening in a Rheumatology Clinic
Osman Bhatty¹ and Michael Lucke¹, ¹Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Depression has long been viewed as a comorbid condition in rheumatic diseases. Population studies have confirmed an increased incidence in patients with rheumatoid arthritis,…
Abstract Number: 0194 • ACR Convergence 2020
Depression Symptoms but Not Clinically Diagnosed Depression Predict Mortality in Rheumatoid Arthritis
Jose Felix Restrepo¹, Inmaculada Del Rincon¹ and Agustin Escalante¹, ¹University of Texas Health Science Center at San Antonio/ Department of Medicine/ Rheumatology, San Antonio, TX
Background/Purpose: Depression and depressive symptoms are common but under-recognized in rheumatoid arthritis (RA). Few studies have examined depression symptoms in RA patients compared to clinically…
Abstract Number: 1733 • ACR Convergence 2020
Patients with Rheumatoid Arthritis and Comorbid Depression Have High Levels of RAPID3 (Routine Assessment of Patient Index Data) and FAST3 (Fibromyalgia Assessment Screening Index) on a Multidimensional Health Assessment Questionnaire (MDHAQ)
Rosa Morlà¹, Tengfei Li², Jose Inciarte-Mundo³, Isabel Castrejon Fernandez⁴, Jose Gómez-Puerta⁵, Raimon Sanmartí⁵ and Theodore Pincus⁶, ¹Hospital Universitari Clínic de Barcelona, Barcelona, Spain, ²Georgetown University, Washigton, ³Hospital Universitari Clínic de Barcelona, Barcelona, ⁴Hospital General Universitario Gregorio Marañón, Chicago, IL, ⁵Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁶Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher comorbid depression and/or fibromyalgia (FM) than the general population. A multidimensional health-assessment questionnaire (MDHAQ) includes two queries…
Abstract Number: 0336 • ACR Convergence 2020
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe
Laure Gossec¹, Jessica Walsh², Kaleb Michaud³, Elizabeth Holdsworth⁴, Steven Peterson⁵, Sophie Meakin⁴, Nicola Booth⁴, Soumya Chakravarty⁶, James Piercy⁴ and Alexis Ogdie⁷, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³University of Nebraska Medical Center, Omaha, NE, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Anxiety and depression are comorbidities among PsA patients. The impact of anxiety and depression on outcomes in PsA patients has not been characterized in…
Abstract Number: 1737 • ACR Convergence 2020
What Influences Fatigue Improvement in Rheumatoid Arthritis? A Prospective Cohort Study
Samar Aboulenain¹, Elie Donath¹ and Ozlem Pala², ¹University of Miami Miller School, West Palm Beach, FL, ²University of Miami Miller School, Fort Lauderdale, FL
Background/Purpose: Fatigue is a common and debilitating complication in patients with rheumatoid arthritis (RA). Its mechanism is not fully elucidated, and when persistent is often…
Abstract Number: 0434 • ACR Convergence 2020
Changes in Mental Health During the COVID-19 Pandemic Among Individuals with Rheumatic Disease
Patricia Katz¹, Sofia Pedro², Kristin Wipfler³, Teresa Simon⁴, Yomei Shaw⁵, Adam Cornish⁶ and Kaleb Michaud⁷, ¹University of California, San Francisco, Novato, CA, ²FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, ⁵Forward, The National Databank for Rheumatic Diseases, East Lansing, MI, ⁶FORWARD, 68134, NE, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Symptoms of both depression and anxiety are often elevated among individuals with rheumatic conditions, and stress levels may play a role in each. Depression,…
Abstract Number: 1804 • ACR Convergence 2020
Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus
Erik Anderson¹, Joanna Fishbein², Joseph Hong², Julien Roeser³, Richard Furie⁴, Cynthia Aranow², Bruce Volpe², Betty Diamond⁵ and Meggan Mackay⁶, ¹Feinstein Institutes for Medical Research, New York, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Northwell Health, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Tryptophan (TRP) is metabolized to kynurenine (KYN), quinolonic acid [QA, a N-methyl D-aspartate receptor (NMDAR) agonist] and kynurenic acid (KA, an NMDAR antagonist). KYN/TRP…
Abstract Number: 0547 • ACR Convergence 2020
Transgender Patients in the Rheumatology Setting
Chantelle Carneiro¹, Jessica Chee², Karen Beattie² and Kimberly Legault², ¹McMaster University, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada
Background/Purpose: Minimal medical research exists regarding transgender patients, particularly within the field of rheumatology. A few case reports note that male to female transitions may…
Abstract Number: 1806 • ACR Convergence 2020
The Association of Interferon-α with Kynurenine/Tryptophan Pathway Activation in Systemic Lupus Erythematosus
Erik Anderson¹, Ying Jin², Sara Goodwin², Julien Roeser³, Richard Furie⁴, Cynthia Aranow⁵, Bruce Volpe⁵, Betty Diamond⁶ and Meggan Mackay⁷, ¹Feinstein Institutes for Medical Research, New York, NY, ²Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Northwell Health, Manhasset, NY, ⁷Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Type I IFN contributes to SLE pathogenesis and stimulates the kynurenine/tryptophan (KYN/TRP) pathway, producing elevated quinolinic acid (QA) levels relative to kynurenic acid (KA)…
Abstract Number: 0551 • ACR Convergence 2020
Physical Performance as a Mediator of the Association Between Depression and Pain in Knee Osteoarthritis
Alan Rathbun¹, Elizabeth Stuart², Michelle Shardell¹, Trang Nguyen², Alice Ryan¹, Joseph Gallo², Michelle Yau³, Megan Schuler⁴ and Marc Hochberg¹, ¹University of Maryland School of Medicine, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Hinda and Arthur Marcus Institute for Aging Research, Boston, MA, ⁴RAND Corporation, Boston, MA
Background/Purpose: Depression is common in knee osteoarthritis (OA), and leads to reduced physical function, which may mediate the effect of depression on pain. However, research…
Abstract Number: 1943 • ACR Convergence 2020
The Prevalence of Anxiety and Depression in Patients with Giant Cell Arteritis
Joana Martinho¹, André Ponte², Eduardo Dourado³, Nikita Khmelinskii¹, Sara Dias⁴, Sofia Barreira⁵, Ana Rita Cruz-Machado¹, Carla Macieira¹, Vítor Teixeira⁶, Ana Rodrigues⁴, Diogo Telles-Correia⁷, João Eurico Fonseca⁸ and Cristina Ponte¹, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, ⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis of the elderly causing blindness if left untreated. However, its hallmark treatment with glucocorticoids…
Abstract Number: 0609 • ACR Convergence 2020
Impact of Depressive Symptoms, Anti-depression Treatment on Direct Medical Costs Among Medicare Beneficiaries with Knee Osteoarthritis (KOA)
Shuang Song¹, Jeffrey Katz² and Elena Losina², ¹Brigham and Women's Hospital, Brighton, MA, ²Harvard Medical School / The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA
Background/Purpose: Depressive symptoms are prevalent among knee OA (KOA) patients and likely lead to additional medical costs. We sought to quantify the prevalence of depressive…

« Previous Page
1
…
5
6
7
8
9
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.